Aquestive Therapeutics Inc
$ 4.14
1.22%
25 Feb - close price
- Market Cap 498,993,000 USD
- Current Price $ 4.14
- High / Low $ 4.23 / 4.05
- Stock P/E N/A
- Book Value -0.03
- EPS -0.70
- Next Earning Report 2026-03-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.26 %
- ROE N/A %
- 52 Week High 7.55
- 52 Week Low 2.12
About
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and marketing various products to address unmet medical needs in the United States and internationally. The company is headquartered in Warren, New Jersey.
Analyst Target Price
$9.22
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-10 | 2025-08-11 | 2025-05-05 | 2025-03-03 | 2024-11-04 | 2024-08-06 | 2024-05-07 | 2024-03-05 | 2023-11-06 | 2023-08-07 | 2023-05-02 | 2023-03-07 |
| Reported EPS | -0.1146 | -0.14 | -0.2235 | -0.1607 | -0.13 | -0.03 | -0.17 | -0.11 | -0.03 | -0.1 | -0.12 | -0.23 |
| Estimated EPS | -0.144 | -0.17 | -0.08 | -0.1325 | -0.13 | -0.12 | -0.08 | -0.08 | -0.11 | -0.12 | -0.19 | -0.23 |
| Surprise | 0.0294 | 0.03 | -0.1435 | -0.0282 | 0 | 0.09 | -0.09 | -0.03 | 0.08 | 0.02 | 0.07 | 0 |
| Surprise Percentage | 20.4167% | 17.6471% | -179.375% | -21.283% | 0% | 75% | -112.5% | -37.5% | 72.7273% | 16.6667% | 36.8421% | 0% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-04 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.13 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: AQST
2026-02-25 10:52:27
Faruqi & Faruqi, LLP is investigating Aquestive Therapeutics, Inc. (NASDAQ: AQST) after the company's stock plunged approximately 40% due to the FDA identifying deficiencies in its New Drug Application for Anaphylm. The deficiencies prevent discussions of labeling and post-marketing requirements, raising concerns about the application's approvability before the January 31, 2026, PDUFA action date. The firm is encouraging investors who suffered significant losses to contact them to discuss their legal options.
2026-02-23 21:23:45
Lake Street Capital Markets has adjusted its valuation model for Aquestive Therapeutics, Inc. (AQST), reducing its price target to $6 from $8 while maintaining a Buy rating. This change reflects an expected delay in the approval of AQST's product, Anaphylm, after the company announced it would resubmit its application in Q3 following a Complete Response Letter. Despite the delay, Aquestive Therapeutics plans to present new clinical results for Anaphylm at the 2026 AAAAI Annual Meeting, highlighting its potential as a non-invasive epinephrine substitute.
2026-02-23 07:00:00
Aquestive Therapeutics, Inc. (NASDAQ:AQST) announced its participation in the Oppenheimer 36th Annual Healthcare Life Sciences Conference, a virtual event taking place on February 25-26. The company's management team will present on February 26th at 12 pm ET and host one-on-one investor meetings. A webcast of the presentation will be available on the company's investor relations website for 30 days.
2026-02-21 12:49:29
Faruqi & Faruqi, LLP is investigating potential claims against Aquestive Therapeutics, Inc. (NASDAQ: AQST) after its stock plunged approximately 40% due to the FDA identifying deficiencies in its New Drug Application (NDA) for Anaphylm. These deficiencies currently prevent labeling and post-marketing discussions, raising concerns about the application's approvability before the January 31, 2026, PDUFA action date. The law firm is encouraging investors who suffered significant losses to contact them to discuss legal options.
2026-02-21 10:52:27
Aquestive Therapeutics announced new clinical data for its Anaphylm™ (dibutepinephrine) sublingual film, demonstrating that it achieved clinically relevant epinephrine plasma concentrations without causing a diastolic blood pressure dip. These findings will be presented at the 2026 AAAAI Annual Meeting. This data reinforces Anaphylm's potential as an alternative to injectable epinephrine for severe allergic reactions, addressing practical barriers to consistent use.
2026-02-21 08:22:49
Aberdeen Group plc recently acquired 625,000 shares of Aquestive Therapeutics (NASDAQ:AQST), valued at over $3.49 million, representing a 0.63% stake in the company. Several other institutional investors also increased their positions in AQST, with hedge funds and institutions now owning approximately 32.45% of the stock. Despite a consensus "Buy" rating and an $8.50 price target from analysts, AQST's stock trades around $3.95, below its 50-day and 200-day moving averages.
